Skip to main content

A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

Completed · Phase 1, Phase 2 · NCT02716116

Conditions: Carcinoma, Non-Small-Cell Lung

At a glance

Research payments reported, 2025
$20,002
U.S. investigators named
4
Sites paid
4
Planned or actual enrollment
324

About the trial

Sponsor
Takeda
Tested
TAK-788 (drug)
Dates
Started 2016-06-16; completion 2026-09-29
Results posted
Not yet

This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this study are to check if there are any side effects from TAK-788, to learn how TAK-788 is processed by the body, and to determine the best dose of TAK-788 to treat this condition. Participants will take TAK-788 capsules with chemotherapy. Participants will continue to take TAK-788 unless they or their doctor decide they should stop this treatment. Participants will take TAK-788 capsules with or without chemotherapy under antidiarrhea prevention to determine the safety of TAK-788 treatment. Non-Asian, non-White participants will take TAK-788 to dete…

From ClinicalTrials.gov, last updated 2026-10-28. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Takeda Pharmaceuticals U.S.A., Inc. reported $20,002 in research payments for this study in 2025 (6 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.